Lynx1 Capital Management Lp Acquires 1,388,794 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) major shareholder Lynx1 Capital Management Lp acquired 1,388,794 shares of the business’s stock in a transaction on Monday, May 19th. The shares were bought at an average price of $1.20 per share, with a total value of $1,666,552.80. Following the completion of the transaction, the insider now directly owns 6,746,141 shares of the company’s stock, valued at approximately $8,095,369.20. The trade was a 25.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

• On Tuesday, May 20th, Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $1,440,000.00.

TScan Therapeutics Trading Up 9.1%

Shares of TCRX stock opened at $1.44 on Friday. The stock has a market cap of $81.49 million, a P/E ratio of -1.36 and a beta of 1.06. TScan Therapeutics, Inc. has a 1 year low of $1.02 and a 1 year high of $9.67. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $2.50.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, research analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TCRX. Needham & Company LLC reiterated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Barclays lowered their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. HC Wainwright dropped their target price on TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Morgan Stanley restated an “overweight” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $7.80.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TCRX. Goldman Sachs Group Inc. lifted its position in TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after purchasing an additional 9,676 shares during the period. Checkpoint Capital L.P. raised its position in shares of TScan Therapeutics by 14.9% in the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock valued at $2,784,000 after buying an additional 261,663 shares in the last quarter. BVF Inc. IL raised its position in shares of TScan Therapeutics by 63.6% in the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock valued at $6,747,000 after buying an additional 1,900,000 shares in the last quarter. Troluce Capital Advisors LLC lifted its holdings in shares of TScan Therapeutics by 58.3% during the 1st quarter. Troluce Capital Advisors LLC now owns 83,758 shares of the company’s stock worth $116,000 after acquiring an additional 30,844 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in shares of TScan Therapeutics during the 1st quarter worth approximately $49,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.